title: Crohn's Disease in which the Patient Developed Aortitis during Treatment with Adalimumab.
abstract: A 23-year-old woman developed aortitis during treatment with adalimumab (ADA) for ileocolic Crohn's disease (CD). The patient complained of a high fever, abdominal pain, diarrhea, hematochezia and arthralgia. Although the ADA therapy resulted in immediate symptom improvement, after six weeks, she again complained of a low-grade fever and abdominal pain, whereas the CD-related symptoms did not worsen. Contrast-enhanced computed tomography revealed thoracoabdominal aortitis, and we therefore started treatment with prednisolone, which immediately improved the fever and abdominal pain. We subsequently tapered the dose of prednisolone and resumed the administration of ADA in order to maintain the CD remission. No further episodes of aortitis relapse were noted after restarting ADA, and the CD currently remains in remission. This is the first report of the onset of aortitis during ADA therapy for CD.
authors.affiliation: Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Japan.
authors.forename: Hiroki
authors.initials: H
authors.lastname: Kiyohara
authors.forename: Tadakazu
authors.initials: T
authors.lastname: Hisamatsu
authors.forename: Katsuyoshi
authors.initials: K
authors.lastname: Matsuoka
authors.forename: Makoto
authors.initials: M
authors.lastname: Naganuma
authors.forename: Hideto
authors.initials: H
authors.lastname: Kameda
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Seta
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Takeuchi
authors.forename: Takanori
authors.initials: T
authors.lastname: Kanai
mesh_terms: D015746:Abdominal Pain / Q000139:chemically induced*; D000068879:Adalimumab / Q000008:administration & dosage / Q000009:adverse effects*; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects*; D001025:Aortitis / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D003424:Crohn Disease / Q000188:drug therapy*; D005260:Female; D005334:Fever / Q000139:chemically induced*; D006801:Humans; D011239:Prednisolone / Q000627:therapeutic use; D012074:Remission Induction; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized; D011239:Prednisolone; D000068879:Adalimumab